A new study published today in Clinical Infectious Diseases suggests that a meningococcal serogroup B vaccine may offer cross-protection against gonorrhea infection.
This new research joins recent studies from Canada, Norway, and New Zealand that also indicated that meningococcal vaccines might be protective against Neisseria gonorrhoeae.
These findings are essential since Neisseria gonorrhoeae is acquiring increasing resistance to available oral antibiotics, and current screening and treatment approaches have not decreased overall gonorrhea incidence.
Read More
